Ignite Creation Date:
2025-12-24 @ 10:54 PM
Ignite Modification Date:
2026-01-01 @ 7:20 AM
Study NCT ID:
NCT05428969
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-01
First Post:
2022-06-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Sponsor:
Faron Pharmaceuticals Ltd
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06-02
Start Date Type:
ACTUAL
Primary Completion Date:
2026-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-04
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-15
First Submit QC Date:
None
Study First Post Date:
2022-06-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-24
Last Update Post Date:
2025-12-01
Last Update Post Date Type:
ESTIMATED